Precipio, Inc. (NASDAQ:PRPO – Get Free Report) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 8,600 shares, a growth of 91.1% from the September 15th total of 4,500 shares. Based on an average trading volume of 10,800 shares, the short-interest ratio is presently 0.8 days. Approximately 0.7% of the company’s stock are sold short.
Precipio Stock Up 2.6 %
Shares of Precipio stock traded up $0.17 during trading on Friday, reaching $6.79. 992 shares of the company traded hands, compared to its average volume of 7,333. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.73 and a quick ratio of 0.59. Precipio has a 1-year low of $4.31 and a 1-year high of $8.99. The company has a 50 day moving average price of $6.25 and a 200-day moving average price of $5.91. The firm has a market capitalization of $10.05 million, a PE ratio of -2.70 and a beta of 1.41.
Precipio (NASDAQ:PRPO – Get Free Report) last released its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter. Precipio had a negative net margin of 22.90% and a negative return on equity of 39.66%. The company had revenue of $4.44 million for the quarter.
Precipio Company Profile
Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
Featured Articles
- Five stocks we like better than Precipio
- Using the MarketBeat Stock Split Calculator
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- How to Plot Fibonacci Price Inflection Levels
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.